New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
November 26, 2012
10:00 EDTSRPT, SMBL, BP, ATRS, RLGY, SNDK, DNKN, LNCO, Z, RDS.A, AAPLOn The Fly: Analyst Initiation Summary
Today's noteworthy initiations include: Apple (AAPL) initiated with a Buy at Citigroup... BP (BP) initiated with an Outperform at Exane BNP Paribas... Dunkin' Brands (DNKN) initiated with a Buy at UBS... Royal Dutch Shell (RDS.A) initiated with an Underperform at Exane BNP Paribas... SanDisk (SNDK) initiated with an Outperform at Credit Suisse... Silicon Laboratories (SLAB) initiated with an Outperform at Pacific Crest... Smart Balance (SMBL) initiated with a Top Pick at RBC Capital... Zillow (Z) initiated with an Equal Weight at Morgan Stanley... Sarepta (SRPT) initiated with an Outperform at Burrill... Realogy (RLGY) initiated with a Buy at CRT Capital... LinnCo (LNCO) initiated with a Strong Buy at Raymond James... Antares Pharma (ATRS) initiated with a Buy at Guggenheim.
News For A;SNDK;SMBL;Z;RLGY;SRPT;LNCO;ATRS From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 >>
October 1, 2015
10:06 EDTSRPTSarepta data support eteplirsen efficacy, says Piper Jaffray
Subscribe for More Information
10:00 EDTSNDKOn The Fly: Analyst Upgrade Summary
Today's noteworthy upgrades include: AMEC Foster Wheeler (AMFW) upgraded to Neutral from Underperform at Macquarie... Ares Capital (ARCC) upgraded to Outperform from Neutral at Macquarie... Celgene (CELG) upgraded to Overweight from Neutral at JPMorgan... Deutsche Boerse (DBOEY) upgraded to Overweight from Underweight at Barclays... Devon Energy (DVN) upgraded on valuation, catlysts at Bernstein... HeartWare (HTWR) upgraded to Market Perform from Underperform at Northland... IBERIABANK (IBKC) upgraded to Buy from Hold at Sandler O'Neill... (JD) upgraded to Buy from Hold at Deutsche Bank... Kirby (KEX) upgraded to Neutral from Underperform at Macquarie... Madison Square Garden (MSG) upgraded to Buy from Hold at Jefferies... Microsoft (MSFT) upgraded to Neutral from Underperform at BofA/Merrill... Newell Rubbermaid (NWL) upgraded to Buy from Neutral at B. Riley... Norfolk Southern (NSC) upgraded to Outperform from Peer Perform at Wolfe Research... Pernod Ricard (PDRDY) upgraded to Buy from Neutral at Goldman... RWE AG (RWEOY) upgraded to Sector Perform from Underperform at RBC Capital... SanDisk (SNDK) upgraded to Overweight from Equal Weight at Morgan Stanley... Steven Madden (SHOO) upgraded to Outperform ahead of earnings turn at Telsey Advisory... Trex Company (TREX) upgraded to Strong Buy from Buy at CL King... Universal Health (UHS) upgraded to Overweight from Sector Weight at KeyBanc... Western Digital (WDC) upgraded on transaction, valuation, momentum at Argus... Workday (WDAY) upgraded to Overweight from Equal Weight at Stephens.
09:20 EDTSRPTOn The Fly: Pre-market Movers
HIGHER: XOMA (XOMA), up 55.7% after announcing an agreement for anti-TGFb program with Novartis (NVS)... Sarepta Therapeutics (SRPT), up 10.6% after announcing additional clinical efficacy and safety data from the company's Phase IIb program of eteplirsen... Huntsman (HUN), up 3.8% after announcing a $150M share repurchase program... Mellanox (MLNX), up 3.2% after raising third quarter revenue guidance. DOWN AFTER EARNINGS: McCormick (MKC), down 3.4%. ALSO LOWER: Capstone Turbine (CPST), down 26.5% after announcing that its preliminary second quarter earnings were notably below management's expectations and analysts' consensus estimates... Concho Resources (CXO), down 3.9% after 7.7M share Spot Secondary priced at $92.50... AGCO (AGCO), down 3.5% after being downgraded to Sell from Neutral at UBS.
07:02 EDTSRPTSarepta: Eteplirsen provided statistically significant advantage in Phase IIb
Subscribe for More Information
06:38 EDTSNDKSanDisk upgraded to Overweight from Equal Weight at Morgan Stanley
Morgan Stanley upgraded SanDisk and maintained its $75 price target. Analyst Joseph Moore expects fundamentals to remain challenged in the short-term but believes downside is limited given the sharp decline in shares and the increased degree of M&A in the group. Moore said Sandisk's assets could be highly valued by a number of industry players and strategic value will be in greater focus.
06:02 EDTZZillow management to meet with JMP Securities
Subscribe for More Information
05:35 EDTSNDKSanDisk implied volatility of 68 at upper end of index mean range
05:12 EDTSNDKStocks with implied volatility movement; SNDK TSO
Subscribe for More Information
September 30, 2015
10:49 EDTSNDKWestern Digital surges on $3.78B investment from China's Unisplendour
Shares of Western Digital (WDC) surged in morning trading after the company said it Unisplendour will take a 15% stake in the U.S. data storage company. WHAT'S NEW: Western Digital and Unisplendour, a unit of China's Tsinghua Holdings, said they entered into a pact under which a Unis subsidiary will invest $3.78B in Western Digital, the companies said. Under the terms of the agreement, Unis will buy the shares at $92.50 each. Unisplendour will own 15% of Western Digital's outstanding shares after the purchase, and have the right to nominate one representative to Western Digital's board of directors, a right that terminates if Unis' ownership falls below 10%. Unis also agreed not to sell any of its Western Digital shares for five years. WHAT'S NOTABLE: In July, the Wall Street Journal reported that Tsinghua Unigroup, which is majority-owned Tsinghua Holdings, offered to buy Micron Technology (MU) for $23B. After several talks and meetings over the matter, Reuters reported on August 28 that Zhao Weiguo, chairman of Tsinghua Unigroup, met with Micron in an attempt to revive takeover talks, but a deal did not come to fruition. Tsinghua Holdings chairman Jinghong Xu said that his company was open to a partnership with Micron if an acquisition deal could not be reached, dealReporter said. Separately, in May, Hewlett-Packard (HPQ) announced that it would sell a 51% stake in its H3C business to Unisplendour for roughly $2.3B. PRICE ACTION: In morning trading, Western Digital shares are up 16.06% to $79.91. OTHERS TO WATCH: Micron, which reports quarterly earnings on Thursday, is up 5.25% to $15.10, HP is up 2.56% to $25.28, SanDisk (SNDK) is up 9.2% to $53.63, Intel (INTC) is up 3.56% to $30.28, and Seagate (STX) is up 5.5% to $44.10.
10:36 EDTSRPTOptions with increasing implied volatility
Subscribe for More Information
09:13 EDTSRPTLeerink reiterates Outperform on BioMarin after time with management
Subscribe for More Information
07:09 EDTSRPTSarepta negative ruling 'more noise than impact, says William Blair
Subscribe for More Information
07:03 EDTSRPTSarepta announces USPTO decision on patent interference proceeding with BioMarin
Subscribe for More Information
September 29, 2015
18:16 EDTSRPTBioMarin receives favorable ruling in use of exon 51 antisense oligonucleotides
BioMarin Pharmaceutical (BMRN) announced that the Patent Trial and Appeal Board issued a decision in favor of BioMarin's claims to the use of exon 51 antisense oligonucleotides to treat Duchenne muscular dystrophy. The BioMarin patent application involved is U.S. Patent Application No. 14/198,992, which is licensed to BioMarin from the Academisch Ziekenhuis Leiden, The Netherlands. The decision by the PTAB is based on motions filed in the patent interference proceeding between BioMarin, due to the acquisition of Prosensa Therapeutics N.V. and Sarepta (SRPT) of Cambridge, Mass as licensee under patents filed by the University of Western Australia. The allowed claims cover the use of the antisense oligonucleotide drisapersen, as well as other antisense oligonucleotides that induce skipping exon 51 for the treatment of Duchenne muscular dystrophy. BioMarin also protects drisapersen under U.S. Patents 7,534,879 and 8,759,507, two patents which were not involved in the interference. The other interference between AZL and UAW related to composition of matter claims for antisense oligonucleotides for Exon 51 skipping, Interference 106,008, remains pending. In Europe, BioMarin's method patent EP 1 619 249 B1 was previously upheld in an amended form after an Opposition procedure initiated by AVI Biopharma (now Sarepta) before the European Patent Office Opposition Division. The upheld claims include the use of 14- to 40-mer antisense oligonucleotides directed to exon 51 in the DMD gene as a potential therapy to treat DMD. Although an appeal procedure is pending, BioMarin currently has an issued and enforceable patent, which encompasses antisense oligonucleotide product/product candidates directed to exons 51 and 46 in Europe.
10:00 EDTSNDKOn The Fly: Analyst Initiation Summary
Subscribe for More Information
September 28, 2015
16:09 EDTSNDKSanDisk initiated with a Buy at Sterne Agee CRT
08:03 EDTSRPTSarepta should be bought on any weakness, says Oppenheimer
Subscribe for More Information
07:12 EDTATRSAntares announces publication of QuickShot Testosterone data in health journal
Subscribe for More Information
September 25, 2015
08:47 EDTSRPTSarepta to host conference call
Conference call to discuss recent data from the Phase IIb study of eteplirsen for Duchenne muscular dystrophy will be held on October 1 at 7 am. Webcast Link
08:37 EDTATRSAntares Pharma could benefit from drug pricing controversy, says Oppenheimer
Subscribe for More Information
1 | 2 | 3 >>

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the disclaimer & terms of use